Related Experiment Video

Updated: Apr 1, 2026

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K

Pharmacogenomics in the treatment of lung cancer: an update

Daniela Morales-Espinosa1,2,3,4, Silvia García-Román5, Niki Karachaliou4

  • 1Translational Research Laboratory, Catalan Institute of Oncology, Hospital Universitari Germans Trias I Pujol, Ctra Canyet s/n, Badalona, 08916 Barcelona, Spain.

Pharmacogenomics
|October 3, 2015
PubMed

Insights

Identifying more molecular markers for non-small cell lung cancer (NSCLC) chemotherapy is crucial. Whole genome studies offer a promising approach to overcome single biomarker limitations and personalize treatment for better patient outcomes.

Area of Science:

  • Genomics
  • Oncology
  • Molecular Biology

Background:

  • Advances in human genome analysis and tumor biology have enabled targeted anticancer therapies.
  • Targeted therapies are developed based on identified tumor-associated mutations and involved pathways.
  • Personalized treatment for non-small cell lung cancer (NSCLC) requires improved molecular markers for drug sensitivity and optimal sequencing.

Purpose of the Study:

  • To identify novel molecular markers predictive of drug sensitivity in NSCLC.
  • To determine optimal drug sequences for tailoring chemotherapy to individual patients.
  • To overcome the limitations of single biomarker approaches through comprehensive genomic analysis.

Main Methods:

  • Analysis of human genome data.
  • Investigation of tumor biology and associated mutations.
  • Exploration of whole genome studies for biomarker discovery.

Main Results:

  • Significant progress in understanding tumor biology and developing targeted therapies.
  • Identification of tumor-associated mutations and pathways.
  • Emerging potential of whole genome studies to surpass single biomarker limitations.

Conclusions:

  • Personalized chemotherapy for NSCLC can be enhanced by matching patient genetic profiles with specific treatments.
  • The reliance on single biomarkers has limited treatment tailoring.
  • Whole genome studies represent a significant advancement towards overcoming these limitations and optimizing NSCLC therapy.
Keywords:
DNA repairdrug metabolismlung cancerpersonalized medicinepharmacogenomicstailored therapytargeted therapy

More Related Videos

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

523
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.4K

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
84
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
147
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
112
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
117
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
98